Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database

Published:2015-05 Issue:2 Volume:108 Page:243-249
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Soranna Davide,Bosetti Cristina,Casula Manuela,Tragni Elena,Catapano Alberico L.,La Vecchia Carlo,Merlino Luca,Corrao Giovanni

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference49 articles.

1. Glycaemic control in type 2 diabetes: targets and new therapies;Tahrani;Pharmacol Ther,2010

2. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;Drucker;Lancet,2006

3. Minireview: update on incretin biology: focus on glucagon-like peptide-1;Brubaker;Endocrinology,2010

4. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus;Patil;Am J Cardiol,2012

5. GLP-1-based therapy for diabetes: what you do not know can hurt you;Butler;Diabetes Care,2010

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration;Annals of Pharmacotherapy;2023-10-26

2. Diabetes mellitus as a consequence of acute severe pancreatitis: Unraveling the mystery;World Journal of Diabetes;2023-08-15

3. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database;Clinical Drug Investigation;2022-09-30

4. Diabetes mellitus and the risk of pancreatitis: A systematic review and meta-analysis of cohort studies;Pancreatology;2020-06

5. The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults;Diabetes Care;2018-04-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3